The Effect of Chlorohexidine Gel on Tissue Healing Following Surgical Exposure of Dental Implants
Launched by RAMBAM HEALTH CARE CAMPUS · Jun 21, 2017
Trial Information
Current as of June 16, 2025
Unknown status
Keywords
ClinConnect Summary
Patients who received implants in our department, and scheduled for surgical uncovering of the implants will be asked to participate in this clinical trial (40) Patients from Department of periodontology, Rambam Health campus, Haifa in Israel will be recruited to Randomized clinical trial; patients will be divided randomly in to 2 groups:
1. Control: following uncovering of the implant a 4 mm height healing abutment will be screwed to the implant (the standard treatment modality) without using Chlorohexidine gel or any other gel.
2. Test group: following implant exposure this group will re...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients who are willing to participate and willing to provide an informed consent.
- • 2. Males and females between the ages 18-80
- • 3. In good general health.
- • 4. Patients who received dental implants and require implant uncovering (if there is more than 1 implant, a minimum radiographic distance of 3 mm will be required between implants).
- Exclusion Criteria:
- • 1. Uncontrolled Type 1 or type 2 diabetes patients( HbA1C\>7).
- • 2. Subjects treated for at least 2 weeks with any medication known to affect soft tissue condition within one month prior to baseline examination (e.g., Phenytoin, Cyclosporine, and chronic use of Bisphosphonates).
- • 3. Patients who underwent guided bone regeneration during implant placement.
- • 4. Patients who used antibiotic during the study or 4 weeks prior to the baseline.
- • 5. Active periodontitis patients.
- • 6. Subjects with presence of active systemic infectious diseases such as: Hepatitis, HIV, history of tuberculosis.
- • 7. Pregnant or lactating females.
About Rambam Health Care Campus
Rambam Health Care Campus is a leading medical institution located in Haifa, Israel, renowned for its comprehensive patient care, advanced research initiatives, and commitment to medical education. As a prominent clinical trial sponsor, Rambam is dedicated to advancing healthcare through innovative research and development, facilitating a wide range of clinical studies across various therapeutic areas. The campus boasts state-of-the-art facilities, a multidisciplinary team of expert researchers and clinicians, and a robust infrastructure that supports rigorous scientific inquiry and ethical standards in clinical trials. By fostering collaboration and leveraging cutting-edge technology, Rambam Health Care Campus aims to enhance treatment options and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Hadar Zigdon, Dr.
Principal Investigator
Rambam Health Care Campus
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials